ClinicalTrials.gg
Not yet recruitingNCT07755150Updated Aug 31, 2026

A Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Subjects With Type 2 Diabetes

A Phase 2 interventional study of DA-302168S and Placebo of DA-302168S in Type 2 Diabetes Mellitus, sponsored by Chendu DIAO Pharmaceutical Group CO., LTD.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by Chendu DIAO Pharmaceutical Group CO., LTD. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
272
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 909 studies in Diabetes Mellitus, Type 2 with a site in China — 205 open to participants now, 228 under way, 46 of them phase 3. Diabetes Mellitus, Type 2 · China.

Planned enrollment
313th of 767
272 · median 199
Started
2026
with 87 others
Phase 2
61 of 909
14 open now
Primary completion
2027-10
later than 148 of 227 live
Registered
864th of 909
by date

Among the 909 studies in Diabetes Mellitus, Type 2 with a site in China, this one is the 313th largest by planned enrollment of the 767 interventional ones that give a count, is one of 88 that started in 2026, is one of 61 in phase 2, reaches primary completion later than 148 of the 227 other live ones, and was the 864th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

205 of the 909 studies in Diabetes Mellitus, Type 2 with a site in China are open now. Recruiting first, the newest first:

200 more — sign in →

All 205 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 909 studies in Diabetes Mellitus, Type 2 with a site in China, or all of them as a file.
02

Study summary

This Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study aims to assess the efficacy, safety, and PK characteristics of DA-302168S tablets in Chinese T2DM participants, and to provide dose-selection evidence for the Phase III confirmatory trial.

Read the detailed description

This Phase II study is designed to enroll approximately 272 adult participants with T2DM. A total of 260 participants will be randomized in a 1:1:1:1:1 ratio to receive DA-302168S at 5 mg, 10 mg, 15 mg, or 20 mg, or matching placebo. An additional open-label cohort (Cohort 5) will enroll 12 participants, all treated with the investigational product at the target dose of 20 mg. The study comprises a screening period of up to 2 weeks, a 4-week run-in period, a 16-week treatment phase, and a 2-week safety follow-up.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Age 18 to 75 years (inclusive), both sexes.
  2. Diagnosed with T2DM according to the Chinese Diabetes Prevention and Treatment Guidelines (2024 Edition) for at least 3 months at screening, and meeting one of the following: (1) on stable metformin monotherapy for ≥8 weeks prior to screening, with a daily dose of ≥1500 mg/day or maximum tolerated dose ≥1000 mg/day, in addition to diet and exercise; stable treatment defined as no change in daily dose; (2) glycemic control by diet and exercise alone for ≥8 weeks prior to screening.
  3. (local laboratory) ≥7.5% and ≤11.0% at screening; and HbA1c (central laboratory) ≥7.5% and ≤10.5% at randomization.
  4. 22.5-40 kg/m² (inclusive), and stable body weight for 3 months prior to screening (weight change \<5%, calculated as [max weight - min weight] / max weight × 100%).

Key Exclusion Criteria:

  1. History of type 1 diabetes, diabetes due to pancreatic injury, or other types of diabetes (excluding gestational diabetes) other than T2DM.
  2. Acute diabetic complications (e.g., diabetic ketoacidosis, lactic acidosis, or hyperosmolar nonketotic coma) within 6 months prior to ICF signing; history of grade 3 hypoglycemia within 6 months prior to ICF signing, or ≥3 episodes of hypoglycemia (blood glucose \<3.9 mmol/L) from 1 month before screening to randomization.
  3. active infection or other diseases (including but not limited to neurological, psychiatric, cardiovascular, endocrine, digestive, respiratory, urinary, hematological, or immunological disorders, except those related to T2DM) within 6 months prior to screening that, in the investigator's judgment, may interfere with trial results or pose additional risks with study drug administration.
  4. Endocrine diseases or history that may significantly affect body weight (e.g., Cushing's syndrome, obesity due to pituitary or hypothalamic disorders), or obesity due to monogenic mutations or genetic obesity syndromes.
  5. Evidence of significant active abnormalities (e.g., lupus or rheumatoid arthritis) requiring systemic therapy during the trial, as judged by the investigator.
  6. Severe chronic diabetic complications at screening (e.g., proliferative retinopathy or maculopathy, painful diabetic neuropathy, intermittent claudication, or diabetic foot).
  7. History or family history of medullary thyroid carcinoma, thyroid C-cell hyperplasia, or multiple endocrine neoplasia type 2.
  8. Hyperthyroidism (including clinical and subclinical) at screening, or hypothyroidism not controlled with stable medication dose (defined as stable dose for ≥3 months with normal thyroid function tests) based on local laboratory reference ranges.
  9. History of acute pancreatitis, or prior chronic pancreatitis or pancreatic injury, or other high-risk factors for pancreatitis.
  10. Acute cholecystitis within 3 months prior to ICF signing, or presence of cholecystitis/cholangitis/bile duct stones/multiple gallstones at screening, or gallbladder-related conditions at screening that, in the investigator's judgment, may predispose to cholecystitis (except those who have undergone cholecystectomy and are deemed eligible by the investigator).
  11. Dysphagia or history of gastrointestinal disorders affecting drug absorption, including but not limited to gastrectomy or resection of any intestinal segment, severe gastrointestinal disease, or clinically evident gastric emptying abnormalities.
  12. Uncontrolled or unstable hypertension at screening, defined as SBP ≥160 mmHg and/or DBP ≥100 mmHg despite regular antihypertensive treatment, or evidence of renal artery stenosis or unstable blood pressure (including orthostatic hypotension).
  13. Clinically significant cardiovascular or cerebrovascular diseases, including but not limited to the following events within 6 months prior to ICF signing or during the run-in period: a. unstable angina; b. heart failure ( class III or IV); c. myocardial infarction; d. coronary artery bypass grafting or percutaneous coronary intervention; e. uncontrolled severe arrhythmias, such as sick sinus syndrome, second- or third-degree atrioventricular block; f. cerebrovascular accidents, such as cerebral infarction or .
  14. Hemoglobinopathies or anemia, such as hemolytic anemia or sickle cell anemia.
  15. History of moderate or severe depression, or PHQ-9 score ≥15 at screening (see Appendix 2), or psychiatric disorders that, in the investigator's opinion, may affect participation.
  16. abnormalities during screening or run-in: heart rate \<50 bpm or >100 bpm; (Fridericia-corrected) >450 ms (male) or >470 ms (female).
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
272 participants (estimated)

Study arms

  • Experimental
    DA-302168S

    Cohort 1-5mg dose group:Participants will receive DA-302168S tablets once daily orally, 16weeks. Cohort 2-10mg dose group:Participants will receive DA-302168S tablets once daily orally, 16weeks. Cohort 3-15mg dose group:Participants will receive DA-302168S tablets once daily orally, 16weeks. Cohort 4-20mg dose group:Participants will receive DA-302168S tablets once daily orally, 16weeks. Cohort 5-20mg dose group:Participants will receive DA-302168S tablets once daily orally, 10weeks.

    Drug: DA-302168S

  • Placebo comparator
    Placebo of DA-302168S

    Cohort 1-5mg dose group:Participants will receive matching placebo tablets orally once daily for 16 weeks. Cohort 2-10mg dose group:Participants will receive matching placebo tablets orally once daily for 16 weeks. Cohort 3-15mg dose group:Participants will receive matching placebo tablets orally once daily for 16 weeks. Cohort 4-20mg dose group:Participants will receive matching placebo tablets orally once daily for 16 weeks.

    Drug: Placebo of DA-302168S

Interventions

  • A small molecule GLP-1R agonist tablet, orally administration, once daily,16weeks.

  • DrugPlacebo of DA-302168S

    Matching placebo tablet will be provided

06

What researchers measure

Primary outcomes

  1. Change from baseline in HbA1c

    measured in %

    Time frame: From baseline (week 1) to week 16

Secondary outcomes

  1. Percentage of participants with HbA1c <7.0% and ≤6.5%

    percentage-point

    Time frame: From baseline (week 1) to week 16

  2. Change from baseline in fasting blood glucose

    Time frame: From baseline (week 1) to week 16

  3. Change from baseline in fasting lipid profile

    Time frame: From baseline (week 1) to week 16

  4. Change from baseline in systolic and diastolic blood pressure

    Time frame: From baseline (week 1) to week 16

  5. Percent changes from baseline in body weight

    Time frame: From baseline (week 1) to week 16

  6. Adverse events, including treatment-emergent adverse events (TEAEs), serious adverse events (SAEs)

    Time frame: From baseline (week 1) to week 18

  7. Change from baseline in fasting C-peptide

    Time frame: From baseline (week 1) to week 16

  8. Change from baseline in fasting insulin

    Time frame: From baseline (week 1) to week 16

  9. Change from baseline in fasting glucagon

    Time frame: From baseline (week 1) to week 16

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Oct 2027, 13 months later.

Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's planned 13 months is close to that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2026
First posted
Aug 10, 2026
StartEst.
Aug 30, 2026
Primary completionEst.
Oct 20, 2027
CompletionEst.
Oct 20, 2027
Last update
Aug 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07755150
Responsible party
Sponsor
First posted
Aug 10, 2026
Start date
Aug 30, 2026 (estimated)
Primary completion
Oct 20, 2027 (estimated)
Completion
Oct 20, 2027 (estimated)
Last update
Aug 31, 2026

Study contacts

xiaolong qin
Contact
qinxiaolong.cn@outlook.com
+8618781997925

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: DA-302168S

Start the discussion